The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
Open accessAbstract
In response to recent advancements in inflammatory bowel disease (IBD) management, the British Society of Gastroenterology (BSG) Clinical Services and Standards Committee (CSSC) has commissioned the BSG IBD section to update its guidelines, last revised in 2019. These updated guidelines aim to complement the IBD standards and promote the use of the national primary care diagnostic pathway for lower gastrointestinal symptoms to enhance diagnostic accuracy and timeliness. Formulated through a systematic and transparent process, this document reflects a consensus of best practices based on current evidence. The guideline, while developed primarily for the UK, is structured to support IBD management internationally. It is endorsed by the BSG executive board and CSSC without external commercial funding, with involvement primarily supported through professional roles in public institutions and the National Health Service (NHS). Methodological revisions since the prior guidelines have enhanced rigor in technical review and development, with methodology details published independently following peer review. In developing the recommendations, 89 clinical experts and stakeholders participated in an online survey, identifying primary outcomes, such as clinical and endoscopic remission, as well as adverse event metrics, all stratified by clinically relevant effect sizes. These guidelines are intended to support clinical decision-making but are not prescriptive, recognizing that individual clinical scenarios may warrant tailored approaches. Further research may inform future revisions as new evidence emerges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
ESPEN guideline: Clinical nutrition in inflammatory bowel disease
Forbes, A., Escher, J., Hébuterne, X., Kłęk, S., Krznaric, Z., Schneider, S., Shamir, R., Stardelova, K., Wierdsma, N., Wiskin, A. E., et al. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2016.12.027 · Cited by 625
RetractedLamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Self-citationHueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., Lehr, H. A., Wirtz, S., Becker, C., Atreya, R., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16432 · Cited by 828
Rutgeerts, P., Hiele, M., Geboes, K., Peeters, M., Penninckx, F., Aerts, R., & Kerremans, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90121-3 · Cited by 743
Halpin, S. J., & Ford, A. C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.260 · Cited by 607
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.047 · Cited by 322
Research works printed but not linked: 748
- Darie, 2023, BSG 2024 IBD guidelines protocol (standard operating procedures), BMJ Open Gastroenterol, 10, 10.1136/bmjgast-2022-001067 · DOI
- Gordon M , Shaban N , Sinopoulou V , et al . n.d. Developing IBD Outcome Effect Size Thresholds to Inform Research, Guidelines, and Clinical Decisions. Inflamm Bowel Dis. doi:10.1093/ibd/izaf085 · DOI
- 10.1136/bmj.324.7341.827 · DOI · Paper page
- 10.1053/j.gastro.2020.12.031 · DOI · Paper page
- Rajagopalan, 2020, Gastrointestinal ultrasound in inflammatory bowel disease care: Patient perceptions and impact on disease-related knowledge, JGH Open, 4, 267, 10.1002/jgh3.12268 · DOI
- 10.1002/ibd.21493 · DOI · Paper page
- Spekhorst, 2014, Performance of the Montreal classification for inflammatory bowel diseases, World J Gastroenterol, 20, 15374, 10.3748/wjg.v20.i41.15374 · DOI
- 10.1038/ajg.2009.177 · DOI · Paper page
- 10.1007/s10350-005-0160-3 · DOI
- 10.1159/000104731 · DOI
- 10.1136/gut.2003.038505 · DOI · Paper page
- 10.1155/2005/269076 · DOI · Paper page
- 10.1016/0016-5085(94)90054-x · DOI · Paper page
- 10.1016/j.cgh.2017.06.016 · DOI · Paper page
- Langholz, 1996, Changes in extent of ulcerative colitis: a study on the course and prognostic factors, Scand J Gastroenterol, 31, 260, 10.3109/00365529609004876 · DOI · Paper page
- 10.1097/01.MIB.0000225339.91484.fc · DOI · Paper page
- 10.1056/NEJM198712243172603 · DOI · Paper page
- 10.1002/ibd.20520 · DOI · Paper page
- Kafil, 2018, Cannabis for the treatment of ulcerative colitis, Cochrane Database Syst Rev, 11
- 10.1136/gutjnl-2011-300486 · DOI · Paper page
- 10.1053/j.gastro.2013.07.024 · DOI · Paper page
- 10.1093/ecco-jcc/jjv111 · DOI · Paper page
- Lee, 2019, Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease, Clin Endosc, 52, 129, 10.5946/ce.2018.042 · DOI
- 10.1016/j.cgh.2015.06.001 · DOI · Paper page
- 10.1097/01.MIB.0000164024.10848.0a · DOI
- Bojic, 2017, Patient Reported Outcome Measures (PROMs) in Inflammatory Bowel Disease: New Data, J Crohns Colitis, 11, S576
- James E , Morris G , Gaurav BN , et al . British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease. Gut 2025. doi:10.1136/gutjnl-2025-335023 · DOI
- Pabla, 2020, Assessing Severity of Disease in Patients with Ulcerative Colitis, Gastroenterol Clin North Am, 49, 671, 10.1016/j.gtc.2020.08.003 · DOI
- 10.1136/gutjnl-2016-312307 · DOI
- Stevens, 2021, Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis, Clin Gastroenterol Hepatol, 19, 2333, 10.1016/j.cgh.2020.08.019 · DOI
- Dulai, 2023, Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis, Clin Gastroenterol Hepatol, 21, 456, 10.1016/j.cgh.2022.07.027 · doi:10.1016/j.cgh.2022.07.027
- Walsh, 2019, Defining Faecal Calprotectin Thresholds as a Surrogate for Endoscopic and Histological Disease Activity in Ulcerative Colitis-a Prospective Analysis, J Crohns Colitis, 13, 424, 10.1093/ecco-jcc/jjy184 · DOI
- Cannatelli, 2021, Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients, Inflamm Bowel Dis, 27, 647, 10.1093/ibd/izaa163 · DOI
- Kawashima, 2023, Low Fecal Calprotectin Predicts Histological Healing in Patients with Ulcerative Colitis with Endoscopic Remission and Leads to Prolonged Clinical Remission, Inflamm Bowel Dis, 29, 359, 10.1093/ibd/izac095 · doi:10.1093/ibd/izac095
- 10.1038/ajg.2015.120 · DOI · Paper page
- 10.1093/ecco-jcc/jjad108 · DOI · Paper page
- Allocca, 2023, Early Intestinal Ultrasound Predicts Long-Term Endoscopic Response to Biologics in Ulcerative Colitis, J Crohns Colitis, 17, 1579, 10.1093/ecco-jcc/jjad071 · DOI
- Allocca, 2021, Point-of-Care Ultrasound in Inflammatory Bowel Disease, J Crohns Colitis, 15, 143, 10.1093/ecco-jcc/jjaa151 · DOI
- Bots, 2021, Intestinal Ultrasound to Assess Disease Activity in Ulcerative Colitis: Development of a novel UC-Ultrasound Index, J Crohns Colitis, 15, 1264, 10.1093/ecco-jcc/jjab002 · DOI
- Goodsall, 2024, Composite Assessment Using Intestinal Ultrasound and Calprotectin Is Accurate in Predicting Histological Activity in Ulcerative Colitis: A Cohort Study, Inflamm Bowel Dis, 30, 190, 10.1093/ibd/izad043 · DOI
- 10.1136/flgastro-2021-102065 · DOI
- 10.1136/gut.2005.082909 · DOI · Paper page
- 10.1097/00054725-200002000-00002 · DOI · Paper page
- Harvey, 1980, A SIMPLE INDEX OF CROHN’S-DISEASE ACTIVITY, The Lancet, 315, 514, 10.1016/S0140-6736(80)92767-1 · DOI · Paper page
- Best, 1976, Development of a Crohn’s Disease Activity Index, Gastroenterology, 70, 439, 10.1016/S0016-5085(76)80163-1 · DOI · Paper page
- Summers, 1979, National Cooperative Crohn’s Disease Study: results of drug treatment, Gastroenterology, 77, 847, 10.1016/0016-5085(79)90385-8 · DOI · Paper page
- 10.1053/gast.2002.31072 · DOI · Paper page
- 10.1056/NEJM199905063401804 · DOI · Paper page
- 10.1097/01.MIB.0000215091.77492.2a · DOI · Paper page
- 10.1515/CCLM.2005.073 · DOI
- E Penna, 2020, Faecal calprotectin is the biomarker that best distinguishes remission from different degrees of endoscopic activity in Crohn’s disease, BMC Gastroenterol, 20, 35, 10.1186/s12876-020-1183-x · DOI
- Shi, 2023, Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis, J Clin Med, 12, 10.3390/jcm12031206 · DOI
- Romero-Mascarell, 2022, Fecal Calprotectin for Small Bowel Crohn’s Disease: Is It a Cutoff Issue?, Diagnostics (Basel), 12, 10.3390/diagnostics12092226 · DOI
- Buisson, 2021, Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn’s Disease Regardless of Disease Location, Inflamm Bowel Dis, 27, 1008, 10.1093/ibd/izaa269 · DOI
- Simon, 2019, Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease?: a systematic review, Intest Res, 17, 160, 10.5217/ir.2018.00114 · DOI
- Zittan, 2018, Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity, JGH Open, 2, 201, 10.1002/jgh3.12068 · doi:10.1002/jgh3.12068
- 10.1111/jgh.14950 · DOI
- 10.1136/flgastro-2016-100686 · DOI
- Kennedy, 2019, Association Between Level of Fecal Calprotectin and Progression of Crohn’s Disease, Clin Gastroenterol Hepatol, 17, 2269, 10.1016/j.cgh.2019.02.017 · DOI
- 10.1055/s-2008-1077445 · DOI
- 10.1093/ECCO-JCC/JJY113 · DOI · Paper page
- 10.1055/s-0034-1391855 · DOI · Paper page
- Tamilarasan, 2022, The diagnostic yield of pan-enteric capsule endoscopy in inflammatory bowel disease: A systematic review and meta-analysis, J Gastroenterol Hepatol, 37, 2207, 10.1111/jgh.16007 · DOI
- Choi, 2017, Effectiveness of Capsule Endoscopy Compared with Other Diagnostic Modalities in Patients with Small Bowel Crohn’s Disease: A Meta-Analysis, Gut Liver, 11, 62, 10.5009/gnl16015 · DOI
- Kopylov, 2017, Diagnostic yield of capsule endoscopy versus magnetic resonance enterography and small bowel contrast ultrasound in the evaluation of small bowel Crohn’s disease: Systematic review and meta-analysis, Dig Liver Dis, 49, 854, 10.1016/j.dld.2017.04.013 · DOI
- Pasha, 2020, Capsule Retention in Crohn’s Disease: A Meta-analysis, Inflamm Bowel Dis, 26, 33, 10.1093/ibd/izz083 · DOI
- 10.1016/j.gie.2011.03.1239 · DOI · Paper page
- 10.1053/j.gastro.2014.04.008 · DOI
- Arulanandan, 2016, Systematic review: Safety of balloon assisted enteroscopy in Crohn’s disease, World J Gastroenterol, 22, 8999, 10.3748/wjg.v22.i40.8999 · DOI
- Zakeri, 2016, Diagnostic imaging and radiation exposure in inflammatory bowel disease, World J Gastroenterol, 22, 2165, 10.3748/wjg.v22.i7.2165 · DOI
- 10.1136/gut.2008.151415 · DOI · Paper page
- Bousorra, 2016, Radiation exposure in Crohn’s disease patients, Tunis Med, 94, 385
- 10.1053/j.gastro.2019.03.051 · DOI · Paper page
- Liu, 2017, A Diagnostic Accuracy Meta-analysis of CT and MRI for the Evaluation of Small Bowel Crohn Disease, Acad Radiol, 24, 1216, 10.1016/j.acra.2017.04.013 · DOI
- 10.1148/radiol.2471070611 · DOI · Paper page
- Greenup, 2016, Medical Imaging in Small Bowel Crohn’s Disease-Computer Tomography Enterography, Magnetic Resonance Enterography, and Ultrasound: “Which One Is the Best for What?”, Inflamm Bowel Dis, 22, 1246, 10.1097/MIB.0000000000000727 · DOI
- 10.1016/S2468-1253(18)30161-4 · DOI · Paper page
- Miles, 2019, Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden, Eur Radiol, 29, 1083, 10.1007/s00330-018-5661-2 · DOI
- 10.1111/j.1365-2036.2011.04710.x · DOI · Paper page
- 10.1016/j.crohns.2013.06.008 · DOI
- 10.1111/j.1365-2036.2007.03556.x · DOI · Paper page
- 10.1053/j.gastro.2020.03.039 · DOI · Paper page
- Castiglione, 2019, One-year clinical outcomes with biologics in Crohn’s disease: transmural healing compared with mucosal or no healing, Aliment Pharmacol Ther, 49, 1026, 10.1111/apt.15190 · DOI · Paper page
- Kumar, 2024, Magnetic Resonance Enterography and Intestinal Ultrasound for the Assessment and Monitoring of Crohn’s Disease, J Crohns Colitis, 18, 1450, 10.1093/ecco-jcc/jjae042 · DOI
- Ponsioen, 2017, Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial, Lancet Gastroenterol Hepatol, 2, 785, 10.1016/S2468-1253(17)30248-0 · DOI · Paper page
- Sands, 2018, The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn’s Disease, J Crohns Colitis, 12, 883, 10.1093/ecco-jcc/jjy055 · DOI
- Herrera-deGuise, 2015, Predictive value of early restoration of quality of life in Crohn’s disease patients receiving antitumor necrosis factor agents, J Gastroenterol Hepatol, 30, 286, 10.1111/jgh.12803 · DOI
- 10.1055/s-2007-1021762 · DOI
- 10.1007/s10620-012-2072-0 · DOI
- Laube, 2018, Oral and upper gastrointestinal Crohn’s disease, J Gastroenterol Hepatol, 33, 355, 10.1111/jgh.13866 · doi:10.1111/jgh.13866
- Dąbkowski, 2019, Clinical significance of endoscopic findings in the upper gastrointestinal tract in Crohn’s disease, Scand J Gastroenterol, 54, 1075, 10.1080/00365521.2019.1656776 · doi:10.1080/00365521.2019.1656776
- 10.1097/MPG.0000000000000239 · DOI · Paper page
- Adamina, 2021, Ecco topical review Optimising reporting in surgery, Endoscopy, and Histopathology: collaboration between s-Ecco, Educom, H-Ecco, Journal of Crohn’s and Colitis, 15, 1089, 10.1093/ecco-jcc/jjab011 · DOI
- Feakins, 2022, ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease, J Crohns Colitis, 16, 343, 10.1093/ecco-jcc/jjab141 · DOI
- 10.1093/ECCO-JCC/JJAD142 · doi:10.1093/ecco-jcc/jjad142
- Magro, 2020, ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology, J Crohns Colitis, 14, 1503, 10.1093/ecco-jcc/jjaa110 · DOI · Paper page
- Sinopoulou V , Nigam GB , Gordon M , et al . Comparative Efficacy and Safety of Endoscopic Modalities for Colorectal Cancer Screening in Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis. Clin Gastroenterol Hepatol 2024. doi:10.1016/j.cgh.2024.11.008 · DOI
- 10.1097/00000478-199808000-00008 · DOI · Paper page
- 10.1111/j.1572-0241.1999.01533.x · doi:10.1111/j.1572-0241.1999.01533.x · Paper page
- 10.1136/gut.32.2.174 · DOI · Paper page
- 10.1136/gut.32.12.1514 · DOI · Paper page
- 10.1136/jclinpath-2013-201885 · DOI · Paper page
- 10.1136/jcp.2006.045336 · doi:10.1136/jcp.2006.045336
- 10.1046/j.1365-2559.2002.01416.x · doi:10.1046/j.1365-2559.2002.01416.x
- 10.1053/j.sempedsurg.2007.04.005 · DOI
- 10.1097/00000478-200211000-00006 · doi:10.1097/00000478-200211000-00006
- 10.1093/ecco-jcc/jjaa036 · DOI
- 10.1097/00000478-198911000-00008 · DOI
- Surawicz, 1984, Rectal biopsy helps to distinguish acute self-limited colitis from idiopathic inflammatory bowel disease, Gastroenterology, 86, 104, 10.1016/0016-5085(84)90595-X · DOI · Paper page
- Rubio, 1994, “Nonspecific” erosions and ulcers of the colonic mucosa, Dig Dis Sci, 39, 821, 10.1007/BF02087429 · doi:10.1007/bf02087429
- 10.1053/j.gastro.2007.08.001 · DOI · Paper page
- 10.1136/gut.47.3.404 · DOI · Paper page
- 10.1136/bmj.1.4979.1315 · DOI · Paper page
- 10.1136/gut.29.5.669 · DOI · Paper page
- 10.1136/gutjnl-2015-310393 · DOI · Paper page
- 10.1093/ecco-jcc/jjaa010 · doi:10.1093/ecco-jcc/jjaa010
- Magro, 2020, Comparing the Continuous Geboes Score With the Robarts Histopathology Index: Definitions of Histological Remission and Response and their Relation to Faecal Calprotectin Levels, J Crohns Colitis, 14, 169, 10.1093/ecco-jcc/jjz123 · doi:10.1093/ecco-jcc/jjz123
- 10.1111/j.1365-2036.2008.03835.x · DOI · Paper page
- 10.1097/MIB.0000000000000155 · DOI
- 10.1016/j.crohns.2014.08.011 · DOI · Paper page
- 10.1007/s00330-008-1290-5 · DOI
- Feakins RM . Transmural histology scores in stricturing Crohn’S disease: seeking to build precision on uncertain foundations. Oxford University Press UK, 2020:721–3. · DOI
- Neri, 2021, Histological scores in inflammatory bowel disease, J Dig Dis, 22, 9, 10.1111/1751-2980.12937 · DOI
- Almradi, 2021, An expert consensus to standardise the assessment of histological disease activity in Crohn’s disease clinical trials, Aliment Pharmacol Ther, 53, 784, 10.1111/apt.16248 · DOI · Paper page
- Salem, 2019, The Role of Histology in Determining Disease Activity, Treatment, and Prognosis: Are We There yet?, Gastrointest Endosc Clin N Am, 29, 437, 10.1016/j.giec.2019.02.010 · DOI
- 10.1016/S0016-5085(98)70476-7 · DOI · Paper page
- Li, 2019, Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn’s Disease, Gastroenterology, 157, 1019, 10.1053/j.gastro.2019.06.037 · DOI
- Novak, 2019, Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn’s disease, Aliment Pharmacol Ther, 49, 1401, 10.1111/apt.15250 · DOI
- Löwenberg, 2019, Vedolizumab Induces Endoscopic and Histologic Remission in Patients With Crohn’s Disease, Gastroenterology, 157, 997, 10.1053/j.gastro.2019.05.067 · DOI
- Villanacci, 2017, Usefulness of Different Pathological Scores to Assess Healing of the Mucosa in Inflammatory Bowel Diseases: A Real Life Study, Sci Rep, 7, 10.1038/s41598-017-07338-x · DOI
- Feagan, 2020, Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study, Lancet Gastroenterol Hepatol, 5, 819, 10.1016/S2468-1253(20)30188-6 · DOI
- 10.1038/ajg.2016.418 · DOI · Paper page
- 10.1136/gutjnl-2015-309598 · DOI · Paper page
- 10.1007/DCR.0b013e31819ad456 · DOI
- 10.1002/ibd.21268 · DOI
- 10.1159/000320415 · DOI
- Hyams, 2017, Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study, Lancet Gastroenterol Hepatol, 2, 855, 10.1016/S2468-1253(17)30252-2 · DOI
- Melson, 2010, Histopathology predictors of medically refractory ulcerative colitis, Dis Colon Rectum, 53, 1280, 10.1007/DCR.0b013e3181e751df · doi:10.1007/dcr.0b013e3181e751df
- Brennan, 2017, Clinical Implications of Histologic Abnormalities in Ileocolonic Biopsies of Patients With Crohn’s Disease in Remission, J Clin Gastroenterol, 51, 43, 10.1097/MCG.0000000000000507 · DOI
- Christensen, 2020, Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn’s Disease than Endoscopic Healing, Clin Gastroenterol Hepatol, 18, 2518, 10.1016/j.cgh.2019.11.056 · DOI
- Yoon, 2021, Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission, Inflamm Bowel Dis, 27, 1277, 10.1093/ibd/izaa301 · DOI
- 10.1053/j.gastro.2018.04.012 · DOI · Paper page
- Alves, 2022, The risk of infections associated with JAK inhibitors in rheumatoid arthritis: a systematic review and network meta-analysis, JCR: Journal of Clinical Rheumatology, 28, e407
- Olivera, 2020, Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis, Gastroenterology, 158, 1554, 10.1053/j.gastro.2020.01.001 · DOI · Paper page
- 10.1002/art.11137 · DOI · Paper page
- Fehily, 2022, Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management, Aliment Pharmacol Ther, 56, 6, 10.1111/apt.16952 · DOI
- 10.1111/j.1572-0241.2008.02050.x · doi:10.1111/j.1572-0241.2008.02050.x
- Greenberg, 2008, Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis, J Rheumatol, 35, 770
- 10.1016/j.diagmicrobio.2010.12.020 · doi:10.1016/j.diagmicrobio.2010.12.020
- Ponce de Leon, 2008, Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population, J Rheumatol, 35, 776
- Park, 2022, Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis, JPM, 12, 507, 10.3390/jpm12030507 · DOI
- 10.1016/j.crohns.2011.09.011 · doi:10.1016/j.crohns.2011.09.011
- Kim, 2021, Low-dose steroids are associated with indeterminate QuantiFERON-TB Gold In-Tube assay results in immunocompetent children, Sci Rep, 11, 10.1038/s41598-021-86053-0 · DOI
- 10.1136/archdischild-2016-310870 · doi:10.1136/archdischild-2016-310870
- Dobler CC . Biologic agents and tuberculosis. Tuberculosis and Nontuberculous Mycobacterial Infections 2017;623–35. doi:10.1128/9781555819866.ch37 · doi:10.1128/9781555819866.ch37
- de Francisco, 2018, Impact of Epstein‐Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease, Aliment Pharmacol Ther, 48, 723, 10.1111/apt.14933 · DOI
- 10.1016/S0140-6736(09)61302-7 · DOI · Paper page
- Zhang, 2022, Impact of Epstein–Barr virus infection in patients with inflammatory bowel disease, Front Immunol, 13, 10.3389/fimmu.2022.1001055 · DOI
- 10.1001/jama.2017.16071 · DOI · Paper page
- 10.1111/apt.12182 · DOI · Paper page
- Winthrop, 2023, Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib, Inflamm Bowel Dis, 29, 85, 10.1093/ibd/izac063 · doi:10.1093/ibd/izac063
- 10.1136/annrheumdis-2020-218510 · DOI · Paper page
- 10.1016/s0140-6736(21)00666-8 · DOI · Paper page
- Giri, 2023, Prevalence of hepatitis B virus and hepatitis C virus infection in patients with inflammatory bowel disease: a systematic review and meta-analysis, Intest Res, 21, 392, 10.5217/ir.2022.00094 · DOI
- Magrì, 2021, Review article: safety of new biologic agents for inflammatory bowel disease in the liver, Eur J Gastroenterol Hepatol, 33, 623, 10.1097/MEG.0000000000002076 · DOI
- Chamberlain, 2014, Azathioprine can be safely used in HIV-infected individuals, AIDS, 28, 447, 10.1097/QAD.0000000000000121 · doi:10.1097/qad.0000000000000121
- Guillo, 2022, Impact of HIV Infection on the Course of Inflammatory Bowel Disease and Drug Safety Profile: A Multicenter GETAID Study, Clin Gastroenterol Hepatol, 20, 787, 10.1016/j.cgh.2020.12.023 · doi:10.1016/j.cgh.2020.12.023
- 10.1097/MIB.0000000000000338 · DOI
- 10.1016/j.suronc.2013.08.002 · DOI
- 10.1056/NEJMra1403718 · DOI · Paper page
- 10.1001/jama.2014.5613 · DOI · Paper page
- Scharl, 2019, Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study, Am J Gastroenterol, 114, 116, 10.1038/s41395-018-0360-9 · DOI
- 10.1053/j.gastro.2012.05.004 · DOI · Paper page
- 10.1111/bjd.15665 · DOI · Paper page
- Sands, 2020, Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis, Clin Gastroenterol Hepatol, 18, 123, 10.1016/j.cgh.2019.04.059 · DOI
- 10.1056/NEJMoa2109927 · DOI · Paper page
- 10.1111/apt.15514 · DOI · Paper page
- 10.1136/ard-2022-223715 · DOI
- 10.1093/ibd/izy243 · DOI
- 10.1136/gut.2010.224154 · DOI · Paper page
- 10.1016/j.crohns.2013.12.013 · DOI · Paper page
- Health. Do . Influenza: The Green Book, Chapter. 1920.
- deBruyn, 2016, Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial, Inflamm Bowel Dis, 22, 638, 10.1097/MIB.0000000000000615 · DOI
- Health Do . Chapter 18. In: Hepatitis B: The Green Book. 2017.
- Belle, 2015, Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases, Eur J Gastroenterol Hepatol, 27, 877, 10.1097/MEG.0000000000000370 · DOI
- 10.1111/jgh.13001 · DOI
- 10.1007/s10620-011-1980-8 · DOI
- 10.1111/j.1365-2036.2012.05110.x · DOI
- Alexander, 2021, SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement, The Lancet Gastroenterology & Hepatology, 6, 218, 10.1016/S2468-1253(21)00024-8 · DOI
- Do. Shingles: The Green Book, Chapter, n.d.:252024.
- 10.1136/gutjnl-2022-327570 · DOI
- Liu, 2023, Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study, EClinicalMedicine, 64, 10.1016/j.eclinm.2023.102249 · DOI
- Din, 2023, Systematic review with network meta-analysis: Risk of Herpes zoster with biological therapies and small molecules in inflammatory bowel disease, Aliment Pharmacol Ther, 57, 666, 10.1111/apt.17379 · DOI
- 10.1093/ecco-jcc/jjab052 · DOI · Paper page
- Department of Health . n.d. Contraindications and special considerations: the green book, Chapter 62013.
- Reich, 2016, Vaccinating patients with inflammatory bowel disease, Gastroenterol Hepatol (Bartlesville), 12, 540
- Chaudrey, 2015, Updates in vaccination: Recommendations for adult inflammatory bowel disease patients, WJG, 21, 3184, 10.3748/wjg.v21.i11.3184 · DOI
- Rahier, 2010, Vaccinations in patients with immune-mediated inflammatory diseases, Rheumatology (Sunnyvale), 49, 1815, 10.1093/rheumatology/keq183 · DOI · Paper page
- Do. Varicella: The Green Book, Chapter 34, 2015.
- 10.14309/ajg.0000000000000152 · DOI · Paper page
200 of 748 shown
Cited by
Gordon, M., de Geus, A., Boruta, M., Banasiuk, M., Benninga, M., Borrelli, O., Darbari, A., Dore‐Stites, D., Gould, M., Hawa, J., et al. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70447 · Cited by 4
Self-citation
Metadata
- Authors
- Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., Chew, T., Colwill, M., Cooney, R., De Marco, G., Din, S., Din, S., Feakins, R., Gasparetto, M., Gordon, H., Hansen, R., Kok, K. B., Lamb, C. A., Limdi, J., Liu, E., Loughrey, M. B., McGonagle, D., Patel, K., Pavlidis, P., Selinger, C., Shale, M., Smith, P. J., Subramanian, S., Taylor, S. A., Tun, G. S. Z., Verma, A. M., & Wong, N. A. C. S.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2025-06
- Volume
- 74
- Issue
- Suppl 2
- Pages
- s1-s101
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W4411623098
- Cited by
- 169
- References
- 20
- FWCI
- 91.44
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-09-26)
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. https://app.cochat.ai/papers/10.1136/gutjnl-2024-334395
- The paper
- Moran, G. W., Gordon, M., Sinopoulou, V., Radford, S. J., Darie, A.-M., Vuyyuru, S. K., Alrubaiy, L., Arebi, N., Blackwell, J., Butler, T. D., Chew, T., Colwill, M., Cooney, R., De Marco, G., Din, S., Din, S., Feakins, R., Gasparetto, M., Gordon, H., . . . Wong, N. A. C. S. (2025). British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025. Gut. https://doi.org/10.1136/gutjnl-2024-334395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.